Focal Leptomeningeal Disease with Perivascular Invasion in EGFR-Mutant Non-Small-Cell Lung Cancer

References

1. 1.↵
   1. Ramotar M,
   2. Barnes S,
   3. Moraes F, et al

   . Neurological death is common in patients with EGFR mutant non-small cell lung cancer diagnosed with brain metastases. Adv Radiat Oncol 2020;5:350–57 doi:10.1016/j.adro.2019.11.002

   CrossRef
2. 2.↵
   1. Liao BC,
   2. Lee JH,
   3. Lin CC, et al

   . Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis. J Thorac Oncol 2015;10:1754–61 doi:10.1097/JTO.0000000000000669 pmid:26334749

   CrossRefPubMed
3. 3.↵
   1. Wolf A,
   2. Donahue B,
   3. Silverman JS, et al

   . Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases. J Neurooncol 2017;134:139–43 doi:10.1007/s11060-017-2497-6 pmid:28536993

   CrossRefPubMed
4. 4.↵
   1. Cagney DN,
   2. Lamba N,
   3. Sinha S, et al

   . Association of neurosurgical resection with development of pachymeningeal seeding in patients with brain metastases. JAMA Oncol 2019;5:703–09 doi:10.1001/jamaoncol.2018.7204

   CrossRef
5. 5.↵
   1. Lin CY,
   2. Chang CC,
   3. Su PL, et al

   . Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC. Medicine (Baltimore) 2019;98:e16766 doi:10.1097/MD.0000000000016766 pmid:31415376

   CrossRefPubMed
6. 6.↵
   1. Sener U,
   2. Matin N,
   3. Yu H, et al

   . Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series. CNS Oncol 2019;8:CNS4 doi:10.2217/cns-2019-0010 pmid:31777268

   CrossRefPubMed
7. 7.↵
   1. Yang JC,
   2. Kim SW,
   3. Kim DW, et al

   . Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol 2020;38:538–47 doi:10.1200/JCO.19.00457 pmid:31809241

   CrossRefPubMed
8. 8.↵
   1. Kleinschmidt-DeMasters BK,
   2. Damek DM

   . The imaging and neuropathological effects of bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis. J Neurooncol 2010;96:375–84 doi:10.1007/s11060-009-9969-2 pmid:19609489

   CrossRefPubMed
9. 9.↵
   1. Takei H,
   2. Rouah E,
   3. Barrios R

   . Intravascular carcinomatosis of central nervous system due to metastatic inflammatory breast cancer: a case report. Neuropathology 2015;35:456–61 doi:10.1111/neup.12206 pmid:25923831

   CrossRefPubMed
10. 10.↵
    1. Groeschel S,
    2. Chong WK,
    3. Surtees R, et al

    . Virchow-Robin spaces on magnetic resonance images: normative data, their dilatation, and a review of the literature. Neuroradiology 2006;48:745–54 doi:10.1007/s00234-006-0112-1 pmid:16896908

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Valiente M,
    2. Obenauf AC,
    3. Jin X, et al

    . Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 2014;156:1002–16 doi:10.1016/j.cell.2014.01.040 pmid:24581498

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Bentolila LA,
    2. Prakash R,
    3. Mihic-Probst D, et al

    . Imaging of angiotropism/vascular co-option in a murine model of brain melanoma: implications for melanoma progression along extravascular pathways. Sci Rep 2016;6:23834 doi:10.1038/srep23834 pmid:27048955

    CrossRefPubMed